The global intrauterine devices market size reached USD 4.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.8 Billion by 2033, exhibiting a growth rate (CAGR) of 3.87% during 2025-2033. The market is propelled by the rising awareness about long-acting reversible contraception (LARC), significant technological advancements in IUD design and insertion techniques, favorable government initiatives promoting family planning and contraception access.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 4.7 Billion |
Market Forecast in 2033
|
USD 6.8 Billion |
Market Growth Rate 2025-2033 | 3.87% |
Growing Awareness about the Long-Acting Reversible Contraception (LARC)
With the rising awareness about the advantages offer by LARC methods such as intrauterine devices (IUDs), more females are preferring these long-term contraceptive solutions. According to a report published by the PLANNED PARENTHOOD, IUDs are one of the most effective birth controls available, with more than 99% of accuracy. On account of this effectiveness, convenience and suitability for numerous patient demographics, such as nulliparous women, adolescents, and individuals seeking long-term contraception, healthcare officials recommend IUDs. Moreover, the societal nature toward contraception changes and educational campaigns promoting LARC techniques, are positively driving the intrauterine devices market growth.
Significant Technological Advancements in IUD Design and Insertion Methods
Technological developments in technology are leading to a better safety, efficacy, and user comfort. For instance, modern IUDs possess organized insertion systems and smaller, more flexible frames, thereby minimizing discomfort during the procedure of placement which further reduces the risk of expulsion or perforation. These developments in the IUD insertion procedures are significantly contributing to a substantial increase in the confidence and consumer satisfaction. Other than this, intrauterine devices developments including hormonal IUDs with lesser hormone doses and prolonged duration of action provide women with more customized contraceptive options while reducing side effects, thereby leading to positive market trends.
Rapid Growth of Distribution Channels and Online Sales Platforms
The expansion of distribution channels, such as clinics, pharmacies, and online sales platforms have increased the access to intrauterine devices and organized the procurement procedure for both healthcare officials and consumers. Conventional brick-and-mortar pharmacies and clinics are the major distribution channels for IUDs, providing customized counseling, insertion services, and follow-up care. Although, the rising popularity of e-commerce platforms in confluence with the telemedicine services are evolving the purchasing and accessing methods of contraceptives. These online sales platforms offer a comfortable and safe means of obtaining IUDs, thus enabling women to research options, compare products, and make informed decisions from their homes. According to the IMARC GROUP, the global telemedicine market has reached US$ 74.7 Billion in 2023, and has reached US$ 465.3 Billion by 2032, exhibiting a CAGR of 22.9% during 2024-2032. Moreover, the inclusion of telemedicine into family planning programs and contraceptive services is further contributing to the intrauterine devices market revenue.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2025-2033. Our report has categorized the market based on product and end-use.
Breakup by Product:
Hormonal intrauterine device (IUD) accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the product. This includes hormonal intrauterine device, and copper intrauterine device. According to the report, hormonal intrauterine device (IUD) represented the largest segment.
Hormonal intrauterine device (IUD) holds the largest intrauterine devices market share on account of their convenience, efficacy, and favorable side effect profile. These devices are used to locally release hormones into the uterus, offering a highly effective contraception along with minimizing menstrual bleeding and cramping. Other than this, hormonal IUDs provide prolonged protection with a few models lasting above 5 years improving user adherence and satisfaction. The adoption of hormonal IUDs is also positively driven by their reversible nature, enabling females to rapidly regain fertility upon removal, making them a preferred choice among healthcare officials and patients.
Breakup by End-Use:
A detailed breakup and analysis of the market based on the end-user have also been provided in the report. This includes hospitals, gynaecology clinics, community healthcare, others.
Hospitals possess a major portion of the market share on account of their role as primary healthcare providers and centers for customized medical procedures. They provide wholistic reproductive health services such as insertion, contraceptive counseling, and follow-up care for intrauterine devices. Furthermore, in according to intrauterine devices market forecast, hospitals often enter into partnerships with government programs and insurance providers so as to guarantee affordability and accessibility of IUD services.
Gynaecology clinics are another major end user concentrating in the reproductive health of women and providing dedicated services for contraceptive counseling, gynaecological exams, and IUD insertion. These clinics offer customized care to specific needs and preferences of women, creating a supportive and confidential environment for contraceptive decision-making.
Whereas, community healthcare centers act as accessible and economical healthcare destinations for weaker sections of the population, such as low-income individuals, rural groups, and marginalized groups, thereby creating a positive intrauterine devices (IUD) market outlook. These centers provide vital reproductive services such as family planning education, contraceptive counseling, and IUD provision.
Breakup by Region:
North America leads the market, accounting for the largest intrauterine devices market share
The market report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America represents the largest as it increases the level of healthcare infrastructure such as developed medical facilities and robust distribution channels, facilitating access to IUDs. Additionally, changing cultural norms toward contraception, along with wholistic sec education programs create a positive intrauterine devices market overview. Other than this, favorable reimbursement policies and insurance coverage for contraceptive services in North America are propelling the market growth.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report | Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Products Covered | Hormonal Intrauterine Device, Copper Intrauterine Device |
End-Uses Covered | Hospitals, Gynaecology Clinics, Community Healthcare, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Companies Covered | Actavis, Bayer, Teva Pharmaceuticals, Allergan, ANI Pharmaceuticals, Eurogine, OCON Medical, Pregna, SMB Corporation, HLL Lifecare, HRA Pharma, Besins HealthCare, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special reque |
The global intrauterine devices market was valued at USD 4.7 Billion in 2024.
We expect the global intrauterine devices market to exhibit a CAGR of 3.87% during 2025-2033.
The increasing cases of unplanned and unwanted pregnancies, along with growing demand for intrauterine devices over other methods of contraception, owing to their compact, safe, and cost-effective properties, are primarily driving the global intrauterine devices market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective contraceptive implants for reducing the risk of the coronavirus infection upon hospital visits and interaction with medical devices, thereby negatively impacting the global market for intrauterine devices.
Based on the product, the global intrauterine devices market can be bifurcated into hormonal intrauterine device and copper intrauterine device. Currently, hormonal intrauterine device exhibits a clear dominance in the market.
On a regional level, the market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global intrauterine devices market include Actavis, Bayer, Teva Pharmaceuticals, Allergan, Eurogine, OCON Medical, Pregna, HLL Lifecare, HRA Pharma, ANI Pharmaceuticals, Besins HealthCare, SMB, etc.